First Amendment to Executive Employment Agreement effective as of May 10, 2022, by and between Kiromic BioPharma, Inc. and Pietro Bersani
Exhibit 10.1
FIRST AMENDMENT TO
EXECUTIVE EMPLOYMENT AGREEMENT
This FIRST AMENDMENT TO EXECUTIVE EMPLOYMENT AGREEMENT (this “Amendment”) is entered into by and between KIROMIC BIOPHARMA, INC., a Delaware corporation (the “Company”), and PIETRO BERSANI (the “Executive”), effective as of May 10, 2022 (the “Effective Date”).
RECITALS:
WHEREAS, the Company and the Executive entered into that certain Executive Employment Agreement, dated effective as of January 27, 2022 (the “Employment Agreement”); and
WHEREAS, the Company and the Executive desire to amend the Employment Agreement as set forth herein;
NOW, THEREFORE, for and in consideration of the foregoing recitals, the promises and mutual covenants and agreements contained in this Amendment, and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties hereto agree as follows:
AGREEMENTS:
- 1 -
[Signature Page Attached]
- 2 -
IT WITNESS WHEREOF, the undersigned parties have executed this Amendment to be effective as of the Effective Date.
COMPANY:
KIROMIC BIOPHARMA, INC.,
a Delaware corporation
By: /s/ Michael Nagel
Name:Michael Nagel
Title:Chairperson of the Board of Directors
EXECUTIVE:
/s/ Pietro Bersani
Pietro Bersani
Signature Page to Amendment